Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orforglipron (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTAIN-1; TRIUMPH-4
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 02 Apr 2026 According to the Novo Nordisk Media Release, the company will present ORION study -a population-adjusted indirect treatment comparison (ITC) evaluating weight loss efficacy and tolerability,using data from the OASIS 4 and ATTAIN-1 phase 3 clinical trials, at Obesity Medicine Association's annual conference in San Diego.
  • 01 Apr 2026 According to an Eli Lilly and Company media release, company has submitted orforglipron for weight management and/or type 2 diabetes in more than 40 countries and plans to launch in each country shortly after approval.
  • 01 Apr 2026 According to an Eli Lilly and Company media release, company announced that the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems supported by ATTAIN clinical trial program.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top